Characterization of the GDP-D-Mannose Biosynthesis Pathway in *Coxiella burnetii*: The Initial Steps for GDP-β-D-Virenose Biosynthesis

Craig T. Narasaki, Katja Mertens, James E. Samuel*

Texas A&M University Health Science Center, College of Medicine, College Station, Texas, United States of America

Abstract

*Coxiella burnetii*, the etiologic agent of human Q fever, is a Gram-negative and naturally obligate intracellular bacterium. The O-specific polysaccharide chain (O-PS) of the lipopolysaccharide (LPS) of *C. burnetii* is considered a heteropolymer of the two unusual sugars β-D-virenose and dihydroxysterptose and mannose. We hypothesize that GDP-β-D-mannose is a metabolic intermediate to GDP-β-D-virenose. GDP-D-mannose is synthesized from fructose-6-phosphate in 3 successive reactions: Isomerization to mannose-6-phosphate catalyzed by a phosphomannose isomerase (PMI), followed by conversion to mannose-1-phosphate mediated by a phosphomannomutase (PMM) and addition of GDP by a GDP-mannose pyrophosphorylase (GMP). GDP-D-mannose is then likely converted to GDP-6-deoxy-D-lyxo-hex-4-ulopyranose (GDP-Sug), a virenose intermediate, by a GDP-mannose-4,6-dehydratase (GMD). To test the validity of this pathway in *C. burnetii*, three open reading frames (CU0671, CU0294 and CU0689) annotated as bifunctional PMI, as PMM or GMD were functionally characterized by complementation of corresponding *E. coli* mutant strains and in enzymatic assays. CU0671, failed to complement an *Escherichia coli* manA (PMM) mutant strain. However, complementation of an *E. coli* manC (GMP) mutant strain restored capsular polysaccharide biosynthesis. CU0294 complemented a *Pseudomonas aeruginosa* algC (GMP) mutant strain and showed phosphoglucomutase activity (PGM) in a *pmm* *E. coli* mutant strain. Despite the inability to complement a manA mutant, recombinant *C. burnetii* PMI protein showed PGM enzymatic activity in biochemical assays. CU0689 showed dehydratase activity and determined kinetic parameters were consistent with previously reported data from other organisms. These results show the biological function of three *C. burnetii* LPS biosynthesis enzymes required for the formation of GDP-D-mannose and GDP-Sug. A fundamental understanding of *C. burnetii* genes that encode PMI, PGM and GMP is critical to fully understand the biosynthetic pathway of GDP-β-D-virenose and LPS structure in *C. burnetii*.

Introduction

Lipopolysaccharide (LPS) is a complex molecule and represents the major component of the outer leaflet of the outer membrane of Gram-negative bacteria. The LPS molecule consists of three structural domains: (1) lipid A, which represent the hydrophobic anchor of the LPS molecule and is responsible for the endotoxic properties, (2) a short non-repeating inner and outer core oligosaccharide, which is attached to lipid A and extends outwardly and (3) the O-specific polysaccharide chain (O-PS), which is composed of repeating sugar units and determines the serological heterogeneity among bacterial isolates. The primary function of LPS is to serve as a permeability barrier against external agents such as hydrophobic antibiotics and to maintain the structural integrity of the Gram-negative cell wall [1].

*C. burnetii*, a Gram-negative small pleomorphic coccobacillus, is the causative agent of the zoonosis Q fever. Q fever manifests in humans generally as an acute, debilitating flu-like illness or less common as chronic Q fever, which develops mainly as endocarditis or hepatitis. *C. burnetii* is a naturally obligate intracellular bacterium and so far no method for generation of specific mutants has been established. *C. burnetii* is considered a potential biological weapon because it consistently causes disability, can be manufactured on a large scale, remains stable under various conditions and can be efficiently disseminated [2]. The U.S. Centers for Disease recently designated *C. burnetii* as a category B bioterrorism agent. There is no licensed vaccine for *C. burnetii* infection in the U.S. because of adverse reactions to killed whole cell vaccination. Therefore, the understanding of *C. burnetii* physiology and vaccine development remains an important public health and U.S. national security objective [3].

Upon serial passage in an immune-incompetent host, virulent *C. burnetii* undergoes a shortening of its LPS, traditionally referred to as phase variation in *Enterobacteriaceae*. Phase variation of *C. burnetii* is characterized by a non-reversible switch from virulent phase I smooth LPS (S-LPS), which has a full length O-polysaccharide (O-PS) chain to an avirulent phase II rough-LPS (R-LPS). The R-LPS variant is missing the O-PS chain and unknown sugar residues located within the outer core oligosaccharide [4]. Previous studies showed that no significant loss of protein content on the surface of *C. burnetii* occurred during phase variation and the only characterized difference between virulent phase I and avirulent phase II isolates is...
LPS [5,6,7,8]. Furthermore, vaccine studies showed that BALBc mice vaccinated with formalin killed whole cell phase I bacteria were protected from *C. burnetii* challenge while mice vaccinated with whole cell phase II bacteria were not protected [8]. These studies highlight the importance of *C. burnetii* LPS.

Structural and compositional studies revealed several unique characteristics of the LPS molecule of *C. burnetii* LPS [9,10,11,12,13,14,15,16,17]. The lipid A moiety contains a typical 1 and 4′ phosphorylated, β-(1→6)-linked D-glucosamine (GlcN) disaccharide backbone, but is tetraacylated [17]. The inner core oligosaccharide is composed of D-mannose (D-Man), D-glycer-D-manno-heptose (D,D-Hep) and 3-deoxy-D-manno-2-octulosonic acid (Kdo), in the molar ratio 2:2:3, comparable to the enterobacterial inner core region [13]. However, composition and structure of the O-PS chain is not entirely resolved. Two unique branched sugar residues, β-D-virenose (6-deoxy-3-C-methyl-D-gulose) and L-dihydrohydroxystreptose (3-C-(hydroxy methyl)-L-lyxose), were detected in heteropolysaccharide fractions of isolated LPS [18,19]. To our knowledge, virenose is not found on the surface structures of any other microorganism except *C. burnetii*. Subsequent studies resolved the structure of virenose, while linkage and chemical compositional analysis indicated that *C. burnetii* O-PS is likely a heteropolymer of 1→4 linked β-D-virenose, dihydrohydroxystreptose and mannose [18,20]. These findings are consistent with the observation that ABC transporter encoding genes *wzm* (CBU0703) and *wzt* (CBU0704) are located in a genomic region associated with O-PS synthesis [21]. ABC transporters are usually involved in biosynthesis of homopolymeric or small repeating units containing heteropolymeric O-PS [1].

Phase variation in *C. burnetii* is accompanied by the deletion of a large chromosomal fragment which contains glycosyl transferases and sugar processing genes required to complete β-D-virenose biosynthesis, O-PS chain elongation and inner membrane transport [21,22]. This deletion is likely the O-PS operon and is responsible for the loss of O-PS in the *C. burnetii* Nine Mile strain RSA439 [21]. Based on the structure of β-D-virenose and the genes located within the deleted region of the *C. burnetii* phase II variant, the in Figure 1 presented GDP-β-D-virenose biosynthesis pathway is proposed. The aim of this study was to demonstrate the biological significance of three *C. burnetii* enzymes for the biosynthesis of GDP-D-mannose and examine the initial steps of GDP-β-D-virenose biosynthesis. The presented data provide fundamental knowledge necessary to further characterize the formation of GDP-β-D-virenose, a novel saccharide, and may help develop potential vaccine candidates such as *in vivo* and *in vitro* generated glycoconjugates.

![Figure 1. Putative GDP-β-D-virenose biosynthesis pathway.](image)

1. F6P, fructose-6-phosphate; PMI, phosphomannose isomerase 2. M6P, mannose-6-phosphate; PMM, phosphomannomutase 3. M1P, mannose-1-phosphate, GMP, GDP-mannose pyrophosphorylase 4. GMD, GDP-mannose 4,6-dehydratase; NADP⁺ nicotinamide adenine dinucleotide phosphate 5. GFS, fucose synthase 6. Ado-Met, S-adenosyl methionine.

doi:10.1371/journal.pone.0025514.g001

---
Results

Bioinformatic analysis was carried out on the C. burnetii enzymes predicted to be responsible for GDP-D-mannose biosynthesis (Table 1). Amino acid sequence alignments indicated that each enzyme had a high degree of similarity to characterized GDP-mannose biosynthesis enzymes. C. burnetii CBU0671 has the bioinformatic signatures of a type II phosphomannomannose isomerase (PMI), a small but growing class of PMIs identified in Gram-negative bacteria [23]. Type II PMIs are bifunctional enzymes that catalyze the isomerisation of fructose-6-phosphate to mannose-6-phosphate and the transfer of GDP to D-mannose-1-phosphate to form GDP-D-mannose [24]. However, C. burnetii CBU0671 appeared to be unrelated to a type I PMI from E. coli EDL933, but contains the conserved PMI active site, which is characteristic of the type II PMIs [23]. C. burnetii CBU0294 is predicted to catalyze the second step in the GDP-mannose biosynthesis pathway, the conversion of D-mannose-6-phosphate to D-mannose 1-phosphate. Amino acid sequence alignment indicated a high degree of identity to P. aeruginosa AlgC, which was shown to be bifunctional and exhibits phosphoglucomutase (PGM) as well as phosphomannomutase (PMM) activity [1,25]. CBU0689 is annotated as GDP-mannose-4,6-dehydratase (GMD) and might provide the virenose biosynthetic intermediate GDP-6-deoxy-D-lyxo-hex-4-ulopyranose (GDP-Sug) by conversion of GDP-D-mannose. Further CBU0671 and CBU0689 are located within a lyxo-4-ulopyranose synthase operon and predicted to encode GDP-D-mannose-4,6-dehydratase and GDP-mannose-6-phosphate epimerase, respectively.

C. burnetii CBU0671 exhibited GDP-mannose pyrophosphorylase (GMP) but not PMI activity

In order to characterize the enzymatic activities of C. burnetii CBU0671, this protein was expressed in its native form and used for complementation of E. coli manA and manC mutant strains, defective for O-PS or CPS synthesis, respectively. To test for PMI activity the CBU0671 containing plasmid pCN606_2 was introduced into the manC mutant strain E. coli CWG634 and O-PS patterns compared to wild type E. coli CWG22 O9a. Inactivation of manA in E. coli CWG364 was shown to abolish synthesis of mannose-6-phosphate, the precursor of GDP-D-mannose and resulted in a R-LPS phenotype [27]. Complementation of E. coli CWG634 with CBU0671 did not result in restoration of an S-LPS phenotype. Analysis of LPS from wild type, mutant and complemented strains using silver stained SDS-PAGE detected only revealed R-LPS chemotypes (data not shown). However, complementation of E. coli CWG634 with E. coli DH5α manA (pCN601a_5), which encoded a type I PMI, resulted in a smooth LPS phenotype (data not shown). To test if CBU0671 exhibits GMP activity, plasmid pCN606_2 was introduced into the E. coli manC mutant strain CWG152 and the CPS pattern was compared to wild type E. coli CWG44 K30 [20,29]. As a positive control, manC from E. coli DH5α was cloned and expressed in its native form and the resulting plasmid, pCN603_1, was introduced into CWG152. CPS isolated from wild-type strain E. coli CWG44, manC mutant strain E. coli CWG152 and complemented strains E. coli CWG152/pCN606_2 and E. coli CWG152/ pCN603_1 were analyzed using silver-stained SDS-PAGE and immunoblot with anti-K30 antiseraum. Complementation of E. coli CWG152 with CBU0671 or E. coli DH5α manC resulted in typical high and low molecular mass CPS bands as detected for the wild type strain (Fig. 2). Taken together these data clearly demonstrated that CBU0671 exhibits GMP activity, but could not complement a type I PMI.

C. burnetii CBU0294 exhibits PMM and PGM activity

The enzymatic function of C. burnetii CBU0294 was evaluated by complementation of an algC mutant of P. aeruginosa PAO1 serotype O5. PMM function of AlgC catalyzes the formation of mannose-1-phosphate, which is a metabolic precursor for synthesis of GDP-D-mannose [25]. The latter is converted to GDP-D-mannose, the sugar residue composing the O5 A-band homopolymor [30]. It has been shown that PMG function of P. aeruginosa AlgC is required for formation of D-glucose-1-phosphate, which is necessary for biosynthesis of UDP-D-glucose, a component of the core heterooligosaccharide [25,31]. Therefore both, PMM and PMG functions of AlgC are required to visualize the O5 A-band homopolymer [30].

To evaluate the PMG activity of C. burnetii CBU0294, pCN620 was transformed into E. coli W1485 pgm::tet and selected on MacConkey agar for the ability to metabolize galactose. E. coli W1485 pgm::tet that harbored pCN620 generated deep red colonies identical to E. coli W1485 wild type, whereas E. coli

Table 1. Predicted C. burnetii proteins catalyzing formation of GDP-D-mannose.

| Bacteria     | Gene       | Gene bank accession no. | % Identity/% Similarity | Putative function    |
|--------------|------------|--------------------------|-------------------------|---------------------|
| C. burnetii  | manA       | AAP90215.1               | 37/54                   | Type II PMI         |
| E. coli      | manA       | AAG56600.1               | 43/61                   | PMI                 |
| E. coli      | manC       | AAG57091.1               | 41/60                   | PGM/GMP             |
| P. aeruginosa| wpbW       | AAG0837.1                |                         |                     |
| P. aeruginosa| algC       | AA089851.2               |                         |                     |
| E. coli      | algC       | AA088707.1               | 55/74                   | PMM/PMM             |
| E. coli      | PMM_PGM    | EFJ67760                 | 32/52                   |                     |
| C. burnetii  | GMP        | NP_819719                | 54/71                   | GMD                 |
| E. coli      | gmd        | ZP_03050267              |                         |                     |

GMD, GDP-mannose-4,6-dehydratase; GMP, GDP-mannose pyrophosphorylase; PGM, phosphoglucomutase; PMI, phosphomannomannose isomerase; PMM, phosphomannomutase.

doi:10.1371/journal.pone.0025514.t001
Determination of PMI, PMM and GMP activities of purified *C. burnetii* proteins

*C. burnetii* CBU0671 and CBU0094 were expressed as His-tagged proteins in *E. coli* DH5a and isolated to near homogeneity. Kinetic analyses of purified enzymes were carried out by measuring initial enzyme specific activity relative to varying concentrations of substrate. Km and Vmax values were determined by Lineweaver-Burk Plot analysis with a regression coefficient greater than 0.99 (Fig. 4). Obtained Km and Vmax values as well as specific enzymatic activity for purified CBU0671 with mannose-1-phosphate or GDP-D-mannose as substrate indicate PMI and GMP activity (Table 2). PMI and GMP activity were also detectable in bacterial crude extracts comparable to *E. coli* ManA and ManC (Table 3). Specific enzymatic activity obtained for purified CBU0294 with mannose-1-phosphate indicates PMM activity, which is also detectable in crude extracts (Table 2 and 3).

GMD activity of *C. burnetii* CBU0689 was tested using the method described by Alberman et al. [32] by expression of the native protein in *E. coli*. Therefore *C. burnetii* CBU0689 was cloned into pBAD and the resulting plasmid, pCN606c-1, transformed *E. coli* DH5a. Enzyme activity was then measured directly in crude extracts by monitoring the increase in GDP-Sug at OD320 (Km = 2.20 L·mmol⁻¹·cm⁻¹) in alkaline conditions. GMD activity for CBU0689 was determined as 14 NKat/mg. Taken together these data clearly show that all three *C. burnetii* open reading frames (ORFs) exhibit the necessary enzymatic activities for formation of GDP-D-mannose and GDP-Sug as intermediates for virenose synthesis.

**Discussion**

The goal of this work was to characterize the enzymatic steps responsible for formation of GDP-D-mannose in *C. burnetii*, which were bioinformatically predicted as the initial steps of GDP-β-D-virenose biosynthesis. Structural evidence of β-D-virenose isolated from the virulent phase I *C. burnetii* RSA493 O-PS further supports this hypothesis [19]. Although *C. burnetii* CBU0671, a predicted bifunctional type II PMI, failed to complement an *E. coli manA* mutant strain (PMI), it did complement an *E. coli manC* mutant strain (GMP). An exhaustive bioinformatic search of the annotated genome failed to reveal an alternative *C. burnetii* PMI. Clustal analysis showed that CBU0671 contained the signature sites observed in other type II PMIs, such as WbpW or AlgA of *P. aeruginosa*; pyrophosphorylase signature, GMP active site, nucleotidytransferase domain, mannose-6-phosphate isomerase domain, zinc binding motif and PMI active site [23]. Although *C. burnetii* failed to complement a manA mutation in *E. coli* in vitro assays using natively formed and His-tagged *C. burnetii* CBU0671 showed specific activities, Km and Vmax values, comparable to previously reported values for PMI and GMP [33]. Differences in regulation or catalytic process might explain the observed distinct activities for CBU0671 in a manA deficient background or in vitro observed enzymatic activities, respectively. Both, type I and type II PMI’s possess a highly conserved motif within the active side, but other proteins have lost the specific catalytic function despite the shared motif [24]. Further investigations, such as complementation of other type II PMI’s are necessary to clearly identify the catalytic activities of CBU0671. Taken together, we report that CBU0671 is a new member of the small and poorly characterized class of proteins known as type II PMIs, based on complementation assays and biochemical characterization.

*C. burnetii* CBU0294 successfully complemented a *P. aeruginosa* O5 algC mutant strain and restored expression of a smooth LPS.
Previous studies showed that \textit{algC} of \textit{P. aeruginosa} O-serotype O5 is involved in formation of D-mannose and D-glucose-1-phosphate, both necessary intermediates for synthesis of the O5 O-specific chain and core oligosaccharide. Therefore inactivation of \textit{algC} leads to a deep rough phenotype in \textit{P. aeruginosa} O5 \cite{25,30}. Restored expression of a smooth LPS by complementation indicates that \textit{C. burnetii} CBU0294 simultaneously carried out PGM and PMM activities in this strain. To further demonstrate that \textit{C. burnetii} CBU0294 also exhibits phosphoglucomutase activity, a \textit{pgm} \textit{E. coli} mutant strain, W1485 \textit{pgm::tet}, was successfully complemented with CBU0294. This finding supports the notation \textit{C. burnetii} CBU0294 is bifunctional and carries out PGM and PMM activities as described for \textit{algC}.

Bioinformatic analysis indicates that CBU0689 encodes a GDP-mannose 4,6-dehydratase (GMD). When compared to \textit{E. coli} GMD, CBU0689 was 52\% identical, 69\% similar on the amino acid level with an \textit{E}_{value} of 5 \times 10^{-12} \cite{32,34}. Specific activity of native \textit{C. burnetii} GMD in crude extracts and its gene location within the LPS associated genome region in \textit{C. burnetii} supports its bioinformatic assignment \cite{26}. GDP-Sug formed by GMD is the metabolic intermediate of GDP-L-fucose, GDP-colitose, GDP-perosamine, GDP-D-rhamnose and GDP-6-deoxy-D-talose \cite{35}. The enzymes required to generate the final steps required for GDP-perosamine (perosamine synthase CBU0830) and GDP-L-fucose (fucose synthase CBU0688) have been identified in the \textit{C. burnetii} genome \cite{26}. However, none of these activated saccharides have been observed in \textit{C. burnetii} with the exception of a single report in which rhamnose was identified by GC-MS in the \textit{C. burnetii} LPS outer core \cite{12}.

Since the characterization of the avirulent \textit{C. burnetii} RSA439 genomic deletion \cite{21}, the enzymatic mechanism of fucose synthase, located within this region has become more clear \cite{36}. Clustal analysis of the \textit{C. burnetii} fucose synthase indicated that it bears the characteristic Ser-Tyr-Lys catalytic triad necessary to catalyze three reactions within a single active site; epimerization at both C3” and C5” and NADPH dependent reduction of the ketone at C4 \cite{36}. Based on these data, the formation of GDP-\beta-D-virenose may ultimately be formed when GDP-L-fucose is modified by the addition of a methyl group at C3” perhaps by CBU0691 and inversion of stereochemistry at the C2” (Fig. S1).

A fundamental understanding of \textit{C. burnetii} LPS biosynthesis and its structure are lacking. The intracellular nature of \textit{C. burnetii}, lack of genetic tools and its status as a select agent has made elucidating these basic physiological mechanism challenging. This study establishes the foundation necessary to fully characterize the GDP-\beta-D-virenose biosynthesis pathway and ultimately the formation of \textit{C. burnetii} O-PS, which is the only known virulence factor of \textit{C. burnetii}.

**Table 2.** Kinetic parameters for \textit{C. burnetii} CBU0671 and CBU0294.

| CBU no. | Tested enzymatic activity | Substrate | Km [\textmu mol L^{-1}] | Vmax [\textmu mol min^{-1}] | Specific activity [mU/mg] |
|--------|--------------------------|-----------|-------------------------|-----------------------------|-------------------------|
| CBU0671 | PMI                      | mannose-6-phosphate | 11600                | 3.59                       | 567                     |
|         | GMP                      | GDP-D-mannose     | 379                   | 0.757                      | 97                      |
| CBU0294 | PMM                      | mannose-1-phosphate | 228                   | 44                         | 4174                    |

GMP, GDP-mannose pyrophosphorylase; PMI, phosphomannose isomerase; PMM, phosphomannomutase.
Materials and Methods

Bacterial strains and growth conditions

Bacterial strains and plasmids used in this study are described in Table 4. All bacterial strains were routinely propagated at 37°C in Luria-Bertani (LB) broth or on LB-1.2% agar plates (Difco Laboratories). When necessary, ampicillin (100 μg/mL), carbenicillin (50 μg/mL), chloramphenicol (34 μg/mL), kanamycin (50 μg/mL), or tetracycline (12.5 μg/mL) was added to the media. *P. aeruginosa* strains were selected on carbenicillin (500 μg/mL) and tetracycline (100 μg/mL), as required.

General DNA methods

DNA isolation and manipulations were carried out in accordance to Sambrook and Russel (2001) [37]. Oligonucleotides used in this study are listed in Table S1. DNA restriction endonucleases, T4 DNA ligase and Accuprime polymerase (Invitrogen) were used as advised by the manufacturer. Electrocompetent *E. coli* and *P. aeruginosa* cells were prepared as described elsewhere [38,39] and transformed using a Bio-Rad Gene-Pulser Transfection Apparatus (200 V, 25 μF, 12.5 kV/cm, 4.7 ms).

Complementation of *E. coli* manA and manC mutant strains with *C. burnetii* CBU0671, including the native stop codon, was amplified from chromosomal DNA of *C. burnetii* RSA 439 with CBU0672F/ncol and CBU0671R and cloned into pBAD for native protein expression. The resulting plasmid, pCN606_2, was used for complementation LPS manA or CPS manC *E. coli* mutant strains.

Table 3. Enzymatic activity of *C. burnetii* CBU0671 and CBU0294 in bacterial crude extracts.

| Tested enzymatic activity | *E. coli* Specific activity [mU/mg] | *C. burnetii* Specific activity [mU/mg] |
|---------------------------|-----------------------------------|-------------------------------------|
| PMI                       | ManA                             | 6148                                 |
|                           |                                   | CBU0671                              |
|                           | ManB                             | ND                                  |
|                           |                                   | CBU0294                              |
| GMP                       | ManC                             | 185                                  |
|                           |                                   | CBU0671                              |

GMP, GDP-mannose pyrophosphorylase; PMI, phosphomannose isomerase; PMM, phosphomannomutase; ND, not detected.

doi:10.1371/journal.pone.0025514.t003

Table 4. Bacterial strains and plasmids used in this study.

| Strain             | Characteristics                       | Reference |
|--------------------|---------------------------------------|-----------|
| *C. burnetii*      | RSA 439, clone 4                      | [48]      |
| *E. coli* DH5x     | F'φ80d.LT1lacZ15M15, recA1, endA1, gusA96, thi1, hsdR17 (rk-mk+), supE44, relA1, deoR, Δ(lacZYA-argF), U169 | Stratagene |
| *E. coli* TOP 10   | F  mcrA Δ(mrr-mcrB4000::Km) Δ(lacZΔM15)F′  [lacZΔM15lacX74 recA1 araD139 galU galK rpsL (StrR) endA1] supE44, relA1, deoR, Δ(lacZYA-argF), U169 | Invitrogen |
| *E. coli* CGW 28   | Trp his lac rpsL cpxX30 (Sm'936::Km) | [27]      |
| *E. coli* CGW 634  | Trp his lac rpsL cpxX30 - manA (Sm'936::Km) | [27]      |
| *E. coli* CGW 44   | his trp lac rpsL (O9::Km30H12; rfb09) | [28]      |
| *E. coli* CGW 152  | CGW44 but O-K-H12rfbM                 | [28]      |
| *E. coli* W1485    | Wild type *E. coli*                  | [25]      |
| *E. coli* W1485 pgm3tet | pgm mutant of W1485                | [25]      |
| *P. aeruginosa* PAO1 | Serotype O5                         | [25]      |
| *P. aeruginosa* PAO1 algC::tet | algC mutant of PA01 (LPS O5') | [25]      |

| Plasmids            |                                                                 |          |
|---------------------|-----------------------------------------------------------------|----------|
| pBAD                | Expression vector, Amp<sup>A</sup>                              | Invitrogen |
| pUCP20              | *P. aeruginosa* shuttle vector, Carb<sup>B</sup>                | [44]     |
| pLS188              | pUCP18, *P. aeruginosa* algC                                     | [25]     |
| pCN601a_5           | pBAD, *E. coli* DH5x manA, native                               | This study |
| pCN601c_A1          | pBAD, *E. coli* DH5x manA, poly-His                             | This study |
| pCN603_1            | pBAD, *E. coli* DH5x cpxB (manC), native                        | This study |
| pCN603a_A4          | pBAD, *E. coli* DH5x cpxB (manC), poly-His                      | This study |
| pCN606_2            | pBAD, CBU0671, native                                           | This study |
| pCN606c_E1          | pBAD, CBU0671, poly-His                                         | This study |
| pCN607a_3           | pBAD, CBU0294, native                                           | This study |
| pCN6072_A2          | pBAD, CBU0294, poly-His                                         | This study |
| pCN608c_1           | pBAD, CBU0689, native                                           | This study |
| pCN620              | pUCP20, CBU0294                                                 | This study |

doi:10.1371/journal.pone.0025514.t004
Complementation of \textit{P. aeruginosa algC} mutant strain with \textit{C. burnetii} CBU0294

CBU0294 was amplified (CUB0294FScal/CUB0294RXbaI) from chromosomal \textit{C. burnetii} RSA 439 DNA and obtained DNA fragment was digested with ScaI and XbaI. CUB0294 was subsequently cloned into the ScaI, XbaI treated shuttle vector pUCP20 to generate pCN620 [44]. Correct insertion of CUB0294 in pCN620 was verified by sequencing. For complementation studies \textit{P. aeruginosa} PAO1 algCtet was transformed with pCN620 and additionally with a \textit{P. aeruginosa algC} containing shuttle vector, pLPS188 [25]. LPS banding patterns from \textit{P. aeruginosa} PAO1 algCtet harboring pCN620 or pLPS188 were analyzed as described under 4.3 and compared to wild type LPS from \textit{P. aeruginosa} PAO1. PAO1 specific antisera (1:1000) was used for detection of CPS expression and traced with horse radish peroxidase-conjugated goat anti-rabbit IgG (1:1000) was used for detection of LPS and CPS wild type strains \textit{E. coli} CG28 (serotype O9a) and \textit{E. coli} CG44 (serotype K330), respectively. Lysates were prepared as described elsewhere [40] and analyzed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and stained with silver nitrate or transferred to nitrocellulose membrane (Bio-RAD) [40,41,42,43]. O9a (1:1000) or K30-specific antiserum (1:1000) was used for detection of LPS and CPS expression and traced with horse radish peroxidase-conjugated goat anti-rabbit IgG(γ) monoclonal antibody (1:5000) with peroxidase substrate in according to the guidelines of the manufacturer (Amersham Bioscience).

Phosphomannoisomerase (PMI) in vitro assay

PMI enzyme activity was determined by monitoring the reduction of NADP\(^+\) at 340 nm (ε\(_{340}\) = 6.22 mM\(^{-1}\) cm\(^{-1}\)) [46]. One unit of enzyme activity was defined as the detection of 1 μmole of product per minute. Concentration of purified enzyme was determined using the Micro BCA Protein Assay (Invitrogen) as described by the supplier. PMI activity was determined by a modified protocol described by Sa-Correia et al. [33]. The reaction mixture in a 1 mL total volume contained 10 μmol of MgCl\(_2\), 1.0 μmol of NADP\(^+\), 1 unit phosphoglucone isomerase, 1 unit glucose-6-phosphate dehydrogenase, 1.1 μmol of D-mannose-6-phosphate in 50 mM tris HCl buffer pH 7.55. MgCl\(_2\), NADP\(^+\) and D-mannose-6-phosphate were dissolved in 50 mM tris HCl buffer pH 7.55 prior to adding them to the reaction mixture. The reaction mixture was equilibrated for 5 min at 25°C and the reaction initiated by adding 50 to 200 μL of crude extract that contained natively formed PMI or 7–15 μg of purified His-tagged PMI (CUB0671).

Cloning and expression of \textit{C. burnetii} GDP-D-mannose synthesis genes for enzyme activity assays

\textit{C. burnetii} CBU0671 (CUB0671F/CUB0671Rpoly-His) and CUB0294 (CUB0294Fpoly-His/CUB0294Rpoly-His) were amplified and subsequently cloned into pBAD for expression of His-tagged proteins. The generated plasmids pCN606a_E1 and pCN606a_A2 were sequenced for correct insertion of target genes and used for transformation of \textit{E. coli} DH5α. As controls \textit{E. coli} DH5α manA and \textit{cbu}B (manB) genes were amplified with EcmANpoly-His and EcmRNpoly-His or EcxBpoly-His and EcxBpoly-His and cloned into pBAD. The resulting plasmids pCN601c_A1 and pCN603a_A4 were sequenced for correct insertion of target genes and used for transformation of \textit{E. coli} DH5α. Expression was induced with 0.2% arabinose for 4 to 8 h at an OD\(_{600}\) of 0.6. Bacteria were harvested (10,000 xg, 10 min, 4°C), resuspended in 10 mM binding buffer (25 mM NaPO\(_4\), 0.5 M NaCl, 10 mM imidazole, pH 8.0) with DNase (10 μg/mL), RNase (10 μg/mL) and lysozyme (10 μg/mL) and incubated for 30 minutes on ice. Cells were lysed by using French press and cell debris separated by centrifugation (24,400 xg, 60 min, 4°C). His-tagged proteins were isolated from supernatants (crudes extracts) using the ProBond purification system as described by the supplier (Invitrogen). Purified proteins were analyzed for purity and size by SDS-PAGE and silver staining or immunoblot analysis with 6×His monoclonal antibody (1:5000, Clontech). PMI, PMM or GMD activity was also determined in bacterial crude extracts that contained natively formed \textit{C. burnetii} proteins.

Phosphoglucomutase (PGM) in vitro assay

PMG activity was determined by monitoring the formation of GDP-D-mannose in \textit{C. burnetii}

\textit{C. burnetii} GDP-D-mannose pyrophosphorylase (GMP) in vitro assay

GMP activity was determined using a modified protocol described by Munch-Peterson et al. [47], monitoring the reduction of NADP\(^+\) (4.6.1.). The reaction mixture in a 1 mL total volume contained 10 μmol of MgCl\(_2\), 1.0 μmol of NADP\(^+\), 0.25 μmol of D-glucose-1,6-diphosphate (ADGD) and 5.5 μmol of D-mannose-1-phosphate in 50 mM tris HCl buffer pH 7.55. \textit{C. burnetii} CBU0294 is annotated as a bifunctional phosphomannomutase (PM) and phosphoglucomutase (PGM). Therefore, the addition of ADGD moved the kinetics of the reaction towards the formation of D-glucuronic-6-phosphate. The reaction mixture was equilibrated for 5 minutes at 25°C and the reaction initiated by adding 50 to 200 μL of crude extract that contained natively formed PM or of 7–15 μg of purified His-tagged PM (CUB0671).
200 µl of crude extract. Endogenous activity in crude extracts of E. coli DH5α carrying the empty pBAD vector were subtracted from the test samples.

**GDP-D-mannose 4,6-dehydratase (GMD) in vitro assay**

CBU0689 was amplified (CBU0689pEC01/CBU0689R) and cloned into pBAD, retaining the native stop codon. The resulting plasmid, pCN606c_1, was used for transformation of E. coli DH5α. Crude extract GMD activity was determined by a modified protocol described by Albermann et al. [32]. The reaction mixture in a total volume of 300 µl contained 10 µmol of MgCl2, 1.0 µmol of NADP+, and 5.5 µmol of GDP-D-mannose in 50 mM tris HCl buffer pH 7.55. After equilibrating for 5 minutes at 37°C, the reaction was initiated by adding 60 µl of prewarmed crude extract. Aliquots of 50 µl were taken every 10 min and added to 950 µl of 37°C 100 mM NaOH. The reaction was incubated for an additional 20 minutes. The formation of GDP-4-keto-6-deoxy-D-mannose was measured directly at OD320 (εmax = 2.2 mM−1 cm−1) [34].

**Supporting Information**

**Figure S1 Clustal analysis of C. burnetii fucose synthase CBU0688 (GFS).** The C. burnetii GFS has the characteristic “Catalytic Triad,” Ser (S) 107-Tyr (Y) 136-Lys (K) 140 boxed in black, observed in SDR family enzymes. Additionally, boxed in red are active sites implicated as the acid/bases involved in promoting the epimerization reactions. (TIF)

**Table S1 Oligonucleotides used in this study.** *Introduced endonuclease restriction sites are underlined. (DOC)

**References**

1. Raetz CR, Whittenfeld C (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635–700.

2. Madariaga MG, Rezai K, Trenholme LA, Weintraub RA (2003) Q fever: a vector-borne zoonotic disease. Annu Rev Microbiol 57: 567–594.

3. Zhang G, Samuel JC (2004) Vaccines against Coxiella infection. Expert Rev Vaccines 3: 577–584.

4. Stoker MG, Fiset P (1956) Phase variation of the Nine Mile and other strains of *Rickettsia prowazekii*. J Exp Med 103: 59–69.

5. Toman R, Skultety L (1996) Structural study on a lipopolysaccharide from *Coxiella burnetii*. Can J Microbiol 32: 1165–1170.

6. Hokkaido T (1980) Steric hindrance of antibody binding to surface proteins of *Coxiella burnetii* by phase I lipopolysaccharide. Infect Immun 56: 892–897.

7. Lukacova M, Kazaar J, Gadzioska E (1994) Coxiella burnetii phase I and II proteins studied by SDS-page. Acta Virol 38: 263–267.

8. Moore A, Hokkaido T (1987) Comparative virulence of intra- and interstrain lipopolysaccharide variants of *Coxiella burnetii* in the guinea pig model. Infect Immun 55: 1144–1150.

9. Zhang G, Russel-Doreguie KE, Andora M, Zhan Y, Hendrix LR, et al. (2007) Mechanisms of vaccine-induced protective immunity against *Coxiella burnetii* infection in BALB/c mice. J Immunol 179: 8372–8380.

10. Toman R, Hussein A, Palkovic P, Ftacek P (2003) Structural properties of lipopolysaccharide of phase I and II populations of *Coxiella burnetii* strain Henzerling and S. Ann N Y Acad Sci 990: 563–567.

11. Schramek S, Mayer H (1982) Different sugar compositions of lipopolysaccharide variants of *Coxiella burnetii* and *Rickettsia burnetii*. Carbohydr Res 94: 47–57.

12. Schramek S, Radziejewska-Lebech J, Mayer H (1985) 5-C-6-Chranced aldoses in lipopolysaccharide of phase I *Coxiella burnetii* and their role as immunodominant factors. Eur J Biochem 148: 455–461.

13. Darwin KD, McFarland RP, Dodgson C, Kido N, et al. (1994) Cloning and analysis of duplicated metabolic and antigenic variants, phase II and RSA 514 (crazy), of the *Coxiella burnetii* nine mile strain. Infect Immun 70: 6726–6733.

14. Denison AM, Massung RF, Thompson HA (2007) Analysis of the O-antigen biosynthesis regions of phase I Isolates of *Coxiella burnetii*. FEMS Microbiol Lett 267: 102–107.

15. Sousa SA, Moreira LM, Leitao JH (2008) Functional analysis of the *Bacillus subtilis* recombinant protein with phosphomannose isomerase and GDP-D-mannose pyrophosphorylase activities. Appl Microbiol Biotechnol 80: 1015–1022.

16. Jensen SO, Reeves PR (1998) Domain organisation in phosphomannose isomerases (types I and II). Biochim Biophys Acta 1382: 5–7.

17. Omuland A, Cockrell DC, Fischer EF, Heinzlen RA (2008) Sustained aerone activity by the obligate intracellular bacterium *Coxiella burnetii*. J Bacteriol 190: 3209–3212.

18. Nohadi R, Paslaw J, Eisen JA, Read TD, Nelson KE, et al. (2003) Complete genome sequence of the Q-fever pathogen *Coxiella burnetii*. Proc Natl Acad Sci U S A 100: 5455–5460.

19. Clarke BR, Cuthbertson L, Whittenfeld C (2004) Nonreducing terminal modifications determine the chain length of polymannose O antigens of *Escherichia coli* and couple chain termination to polymer export via an ATP-binding cassette transporter. J Biol Chem 279: 35709–35718.

20. Jayaratne P, Bronner D, MacLachlan P, Dodgson C, Kido N, et al. (1994) Sequence analysis of the phase II genome sequence of the Q-fever pathogen *Coxiella burnetii*. J Biol Chem 270: 33040–33047.

21. Hoover TA, Culp DW, Voight MH, Williams JC, Thompson HA (2002) Chromosomal DNA deletions explain phenotypic characteristics of two antigenic variants, phase II and RSA 514 (crazy), of the *Coxiella burnetii* nine mile strain. Infect Immun 70: 6726–6733.

22. Denison AM, Massung RF, Thompson HA (2007) Analysis of the O-antigen biosynthesis regions of phase II Isolates of *Coxiella burnetii*. FEMS Microbiol Lett 267: 102–107.

23. Sousa SA, Moreira LM, Leitao JH (2008) Functional analysis of the *Bacillus subtilis* recombinant protein with phosphomannose isomerase and GDP-D-mannose pyrophosphorylase activities. Appl Microbiol Biotechnol 80: 1015–1022.

24. Jensen SO, Reeves PR (1998) Domain organisation in phosphomannose isomerases (types I and II). Biochim Biophys Acta 1382: 5–7.

25. Omsland A, Cockrell DC, Fischer EF, Heinzlen RA (2008) Sustained aerone activity by the obligate intracellular bacterium *Coxiella burnetii*. J Bacteriol 190: 3209–3212.

26. Nohadi R, Paslaw J, Eisen JA, Read TD, Nelson KE, et al. (2003) Complete genome sequence of the Q-fever pathogen *Coxiella burnetii*. Proc Natl Acad Sci U S A 100: 5455–5460.

27. Clarke BR, Cuthbertson L, Whittenfeld C (2004) Nonreducing terminal modifications determine the chain length of polymannose O antigens of *Escherichia coli* and couple chain termination to polymer export via an ATP-binding cassette transporter. J Biol Chem 279: 35709–35718.

28. Jayaratne P, Bronner D, MacLachlan PR, Dodgson C, Kido N, et al. (1994) Sequence analysis of the phase II genome sequence of the Q-fever pathogen *Coxiella burnetii*. J Biol Chem 270: 33040–33047.

29. Whitfield C (2006) Biosynthesis and assembly of capsular polysaccharides in *Escherichia coli*. Carbohydr Res 306: 291–296.

30. King JD, Kocincova D, Westman EL, Lam JS (2009) Review: Lipopolysaccharide biosynthesis of mucoid and nonmucoid *Pseudomonas aeroginosa* and *Pseudomonas aeruginosa* overproduction of phosphomannose isomerase, phosphomannomutase, and GDP-mannose pyrophosphorylase by overexpression of the phosphomannose isomerase (pmi) gene. J Bacteriol 191: 3224–3231.

**Author Contributions**

Conceived and designed the experiments: CTN KM JES. Performed the experiments: CTN. Analyzed the data: CTN. Contributed reagents/materials/analysis tools: JES. Wrote the paper: CTN KM.
34. Albermann C, Distler J, Piepersberg W (2000) Preparative synthesis of GDP-beta-L-fucose by recombinant enzymes from enterobacterial sources. Glycobiology 10: 875–881.
35. Samuel G, Reeves P (2003) Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor synthesis and O-antigen assembly. Carbohydr Res 338: 2503–2519.
36. Lau ST, Tanner ME (2008) Mechanism and active site residues of GDP-fucose synthase. J Am Chem Soc 130: 17593–17602.
37. Sambeok J, Russell D (2001) Molecular Cloning: A Laboratory Manual. Cold Spring HarborNY: Cold Spring Harbor Laboratory Press.
38. Choi KH, Kumar A, Schweizer HP (2006) A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J Microbiol Methods 64: 391–397.
39. Dower WJ, Miller JF, Ragsdale CW (1988) High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16: 6127–6145.
40. Hitchcock PJ, Brown TM (1983) Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 154: 269–277.

34. Albermann C, Distler J, Piepersberg W (2000) Preparative synthesis of GDP-beta-L-fucose by recombinant enzymes from enterobacterial sources. Glycobiology 10: 875–881.
35. Samuel G, Reeves P (2003) Biosynthesis of O-antigens: genes and pathways involved in nucleotide sugar precursor synthesis and O-antigen assembly. Carbohydr Res 338: 2503–2519.
36. Lau ST, Tanner ME (2008) Mechanism and active site residues of GDP-fucose synthase. J Am Chem Soc 130: 17593–17602.
37. Sambeok J, Russell D (2001) Molecular Cloning: A Laboratory Manual. Cold Spring HarborNY: Cold Spring Harbor Laboratory Press.
38. Choi KH, Kumar A, Schweizer HP (2006) A 10-min method for preparation of highly electrocompetent Pseudomonas aeruginosa cells: application for DNA fragment transfer between chromosomes and plasmid transformation. J Microbiol Methods 64: 391–397.
39. Dower WJ, Miller JF, Ragsdale CW (1988) High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res 16: 6127–6145.
40. Hitchcock PJ, Brown TM (1983) Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 154: 269–277.